Market news

On Thursday, Biofrontera (NASDAQ:BFRI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive financial

Detailed price information for Biofrontera Inc (BFRI-Q) from The Globe and Mail including charting and trades.

Moby summary of Biofrontera Inc.'s Q2 2026 earnings call

Biofrontera Inc (BFRI) reports a 45% jump in Ameluz prescriptions and improved gross margins, while navigating competitive pressures and a widened net loss in Q2 2026.

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of +70.59% and +33.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026. Second Quarter 2026 Highlights Net product revenue of $12.0 million, an increase of 32.9% compared to $9.0 million in the prior-year period.Gross margin of 80%, compared to 71% in the pri

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED® lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026. Management will host a conference call and webca